JKE-1674
JKE-1674 is an orally active glutathione peroxidase 4 (GPX4) inhibitor and an active metabolite of GPX4 inhibitor ML-210. JKE-1674, an analog of ML-210 in which the nitroisoxazole ring is replaced with an α-nitroketoxime. JKE-1674 can convert into a nitrile oxide JKE-1777. JKE-1674 kills LOX-IMVI cells in a manner that is equipotent to ML-210 and is completely rescued by ferroptosis inhibitors[1][2][3].
Product Specifications
CAS Number
2421119-60-8
UNSPSC
12352005
Target
Ferroptosis; Glutathione Peroxidase
Type
Reference compound
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/jke-1674.html
Concentration
10mM
Purity
99.54
Solubility
DMSO : 100 mg/mL (ultrasonic) |Ethanol : ≥ 50 mg/mL
Smiles
O=C(N1CCN(C(C2=CC=C(Cl)C=C2)C3=CC=C(Cl)C=C3)CC1)/C(C[N+]([O-])=O)=N/O
Molecular Formula
C20H20Cl2N4O4
Molecular Weight
451.30
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
GPX4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Major Vault Protein (MVP) (1032), CF740 conjugate, 0.1mg/mL
Tyrosinase (T311), CF647 conjugate, 0.1mg/mL
TYRP1 (Tyrosinase Related Protein 1) (TA99), CF568 conjugate, 0.1mg/mL
SOX2 (Transcription Factor) (SOX2/1791), CF647 conjugate, 0.1mg/mL
